GlassScriptPhysician profile
Fouad Batah
NPI 1285618983
$19,643.78
in general payments reported to CMS, 2019-2025
62 companies · $2,111 in 2025
The $2,111 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,282 · 2020: $2,602 · 2021: $3,369 · 2022: $2,986 · 2023: $2,908 · 2024: $2,386 · 2025: $2,111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,385 · Education: $20.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,384.71 |
| Education | $20.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,185.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,892.23 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $1,589.31 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,563.85 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,502.78 | 2019-2025 | Repatha, Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $1,248.24 | 2019-2025 | Austedo Xr, Austedo, Ajovy |
| Pfizer INC. | $861.04 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $805.33 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $756.20 | 2019-2025 | |
| Abbvie INC. | $748.87 | 2021-2025 | Vraylar, Ubrelvy, Linzess |
| Merck Sharp & Dohme LLC | $701.30 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Amarin Pharma, INC. | $491.37 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $457.11 | 2021-2023 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $438.67 | 2019-2023 | |
| Abbott Laboratories | $346.59 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fouad Batah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.